- Home
- SXTC vs ZVSA Comparison
SXTC vs ZVSA Comparison
Compare SXTC & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- ZVSA
- Stock Information
- Founded
- SXTC 2005
- ZVSA 2014
- Country
- SXTC China
- ZVSA United States
- Employees
- SXTC N/A
- ZVSA N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- ZVSA Health Care
- Exchange
- SXTC Nasdaq
- ZVSA Nasdaq
- Market Cap
- SXTC 2.5M
- ZVSA 2.3M
- IPO Year
- SXTC 2019
- ZVSA N/A
- Fundamental
- Price
- SXTC $0.39
- ZVSA $1.08
- Analyst Decision
- SXTC
- ZVSA Strong Buy
- Analyst Count
- SXTC 0
- ZVSA 1
- Target Price
- SXTC N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- SXTC 206.0K
- ZVSA 3.6M
- Earning Date
- SXTC 01-01-0001
- ZVSA 11-14-2024
- Dividend Yield
- SXTC N/A
- ZVSA N/A
- EPS Growth
- SXTC N/A
- ZVSA N/A
- EPS
- SXTC N/A
- ZVSA N/A
- Revenue
- SXTC $1,928,497.00
- ZVSA N/A
- Revenue This Year
- SXTC N/A
- ZVSA N/A
- Revenue Next Year
- SXTC N/A
- ZVSA N/A
- P/E Ratio
- SXTC N/A
- ZVSA N/A
- Revenue Growth
- SXTC N/A
- ZVSA N/A
- 52 Week Low
- SXTC $0.37
- ZVSA $1.05
- 52 Week High
- SXTC $6.39
- ZVSA $42.35
- Technical
- Relative Strength Index (RSI)
- SXTC 29.34
- ZVSA 27.91
- Support Level
- SXTC $0.45
- ZVSA $1.34
- Resistance Level
- SXTC $0.51
- ZVSA $1.89
- Average True Range (ATR)
- SXTC 0.06
- ZVSA 0.25
- MACD
- SXTC -0.01
- ZVSA -0.08
- Stochastic Oscillator
- SXTC 5.97
- ZVSA 1.29
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.